{"id":"W3030001291","doi":"10.1200/jco.2020.38.15_suppl.5516","title":"Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Clinical endpoint; Abiraterone acetate; Urology; Androgen deprivation therapy; Doubling time; Tolerability; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00159068,0.0002085145,0.00172839,0.0001306617,0.00004136742,0.00001221562,0.0001735958,0.000142448,0.00009820738],"category_scores_gemma":[0.002015451,0.0001343386,0.0001668571,0.0003467082,0.0002179993,0.0001415006,0.00005138482,0.0009585369,0.000005041886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002928438,"about_ca_system_score_gemma":0.002833218,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009203523,"about_ca_topic_score_gemma":0.00405284,"domain_scores_codex":[0.9949059,0.000670377,0.002804065,0.0003561988,0.0009379045,0.0003255845],"domain_scores_gemma":[0.9945953,0.002258003,0.001821407,0.000193586,0.0006374445,0.0004942435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7819016,0.01276495,0.1764854,0.000048672,0.001325648,0.002126944,0.003376748,0.0003261349,0.0002089347,0.000002606316,0.0006120775,0.02082028],"study_design_scores_gemma":[0.4824107,0.1559129,0.3559229,0.0002392599,0.0008762528,0.000003843785,0.002721058,0.0003430864,0.0001462766,0.00001341992,0.0012594,0.0001510141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941733,0.0001604089,0.000007244092,0.003544635,0.0005117663,0.001155678,0.0001743702,0.000005732434,0.0002668063],"genre_scores_gemma":[0.9985638,0.0002477815,0.0004921685,0.0001659204,0.0003502137,0.00002361914,0.00004016166,0.00002076375,0.00009558524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2994909,"threshold_uncertainty_score":0.5478168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2538544650300776,"score_gpt":0.4959335255756794,"score_spread":0.2420790605456018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}